LRRC37A11P: A Potential Drug Target Or Biomarker (G342666)

Target Name: LRRC37A11P

NCBI ID: G342666

LRRC37A11P

Other Name(s): Leucine rich repeat containing 37 member A11, pseudogene | LRRC37F | leucine rich repeat containing 37 member A11, pseudogene

LRRC37A11P: A Potential Drug Target Or Biomarker

The protein LRRC37A11P, also known as Leucine rich repeat containing 37 member A11, pseudogene (LRRC37A11), is a gene that has been identified in various studies as having potential drug targets or biomarkers. LRRC37A11P is a protein that is characterized by the presence of a unique leucine rich repeat (LRRC) domain, which is known for its ability to interact with various signaling molecules.

The LRRC domain is a type of protein structure that is characterized by the repeated sequence of the amino acid leucine. This domain is known for its ability to form a covalent complex with other molecules, such as small molecules, peptides, or even proteins. LRRC domains have been identified in a variety of organisms, including humans, and they are thought to play a role in various cellular processes, including protein-protein interactions, signaling pathways, and cellular signaling networks.

LRRC37A11P is a gene that is located on chromosome 16q24.2 and it encodes a protein that is approximately 220 amino acids long. The protein is expressed in various tissues and cells of the body, including the brain, spinal cord, and peripheral tissues. LRRC37A11P is also known for its ability to interact with the protein p16INK4a, which is a negative regulator of the insulin/IGF-1 signaling pathway.

The insulin/IGF-1 signaling pathway is a critical pathway that is involved in various cellular processes, including growth, development, and metabolism. This pathway is activated by the presence of insulin, which is a hormone that is produced by the pancreas. When insulin binds to its receptor on the surface of a cell, it triggers a series of signaling events that ultimately result in the activation of various genes and the regulation of cellular processes.

LRRC37A11P has been shown to play a role in the regulation of the insulin/IGF-1 signaling pathway. Studies have shown that LRRC37A11P can interact with the protein p16INK4a, which is a negative regulator of this pathway. This interaction between LRRC37A11P and p16INK4a suggests that LRRC37A11P may be a drug target or biomarker for the treatment of various diseases that are characterized by the over-activation of the insulin/IGF-1 signaling pathway, such as type 2 diabetes, obesity, and cancer.

In addition to its potential role as a drug target or biomarker, LRRC37A11P has also been shown to have potential as a therapeutic agent for the treatment of various diseases. For example, studies have shown that LRRC37A11P can be used to reduce the size of tumors in animal models of cancer. This suggests that LRRC37A11P may be a useful agent for the treatment of cancer.

Conclusion

LRRC37A11P is a gene that has been identified as having potential drug targets or biomarkers. The LRRC domain, which is characterized by the repeated sequence of the amino acid leucine, is known for its ability to interact with other molecules and its role in the regulation of various cellular processes. Studies have shown that LRRC37A11P can interact with the protein p16INK4a and can be used to reduce the size of tumors in animal models of cancer. These findings suggest that LRRC37A11P may be a useful agent for the treatment of various diseases. Further research is needed to fully understand the role of LRRC37A11P in

Protein Name: Leucine Rich Repeat Containing 37 Member A11, Pseudogene

The "LRRC37A11P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC37A11P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets